CD33 and acute myeloid leukemia: Interestingly, a number of patients with AML were found to be refractory to this type of therapy because of the presence of a single nucleotide polymorphism (SNP) (rs12459419 (C> T Ala14Val)) that leads to the loss of the CD33 V-type Ig domain [64].